Background: Screening programmes for contralateral carcinoma in situ (CIS) testis in patients with unilateral germ-cell cancer (GCC) have never been evaluated. We investigated the effect of screening for contralateral CIS in a large nationwide, population-based study.
introduction Testicular germ-cell cancer (GCC) is preceded by a non-invasive precursor, carcinoma in situ (CIS), which is present in the contralateral testicle in ∼5%-6% of all GCC cases [1, 2] . CIS can be detected by testicular biopsy. If left untreated, the estimated risk of developing an invasive cancer is 50% within the first 5 years [2] . The risk factors for contralateral CIS in GCC patients include cryptorchidism, young age, infertility, and atrophy of the testicles [3] [4] [5] .
Screening for contralateral CIS is controversial. The European Association of Urology recommends biopsy in patients with small testicular volume (<12 ml), a history of cryptorchidism, or poor spermatogenesis [4] . The National Comprehensive Cancer Network recommends biopsy in cases of cryptorchidism, suspect ultrasound with intratesticular abnormalities, or marked atrophy of the testicle [5] . Screening for contralateral CIS was introduced in 1984 in eastern Denmark in unselected patients with unilateral testicular GCC and extended nationwide in 1992. We evaluated the long-term effect of screening for and treatment of contralateral CIS on the development of metachronous GCC. materials and methods A contralateral biopsy concomitantly with orchiectomy was offered to 4130 patients with GCC diagnosed in 1984-2007 (screened cohort), and 462 patients with GCC diagnosed in 1984-1988 comprised the unscreened cohort. The unscreened patients were diagnosed in western Denmark, before screening became nationwide. Except from not being screened, there was no selection bias. The 817 exclusions from the analysis are shown in Figure 1 . Only patients managed with the current standard regimens [bleomycinetoposide-cisplatin (BEP), retroperitoneal radiotherapy, or surveillance] were included in order to obtain a uniformly treated group.
If CIS was detected, patients were offered radiotherapy to the testicle at doses of 14-20 Gy. Since 2001, 16 Gy has been the recommended standard dose. Radiotherapy for contralateral CIS was routine from 1986 for patients followed on surveillance [6] . Patients in whom contralateral CIS was diagnosed before 1986 received scrotal radiotherapy once it became standard treatment. After 1998, radiotherapy was also given to patients with CIS and metastatic disease, irrespective of chemotherapy [7] . A biopsy was carried out 1 year after radiotherapy to ensure eradication of CIS. The patients were followed up for 10 years, with annual clinical and ultrasound examinations of the affected testicle.
Danish residents have a unique personal identification number, which allows data linkage among national registers. By using these numbers, we obtained up-to-date information on vital status, relapses, emigration, disappearance, and death [8] [9] [10] . Cases of metachronous GCC, defined as contralateral GCC diagnosed at least 6 months after diagnosis of the primary tumour, were identified. Initially CIS-negative biopsies were revised by three authors with experience in testicular histopathology (NES, BGT, ER-DM) using immunohistochemical staining for placental-like alkaline phosphatase (PLAP) and other markers, such as D2-40/podoplanin, OCT3/4, and MAGE A4. Immunohistochemical staining for PLAP has been mandatory in all testicular biopsies examined at the Copenhagen University Hospital since November 1996, and was later gradually implemented in other hospitals in Denmark.
The study protocol was approved by the National Data Protection Board (file number 2012-41-0751), and revision of CIS-negative biopsies in patients with metachronous GCC was approved by the regional ethical committee (file number H-1-2012-107).
statistical analysis
The cumulative incidence of metachronous GCC was estimated for the screened and the unscreened cohort with death as competing risk and compared by the method proposed by Gray [11] . Patients were censored at the time of emigration, disappearance, second orchiectomy for a reason other than cancer, or the end of the study on 30 November 2012, whichever occurred first. In a Cox proportional hazards model, we adjusted for possible explanatory covariates related to metachronous GCC, which were cohort (screened versus unscreened), treatment of primary GCC (surveillance, BEP, or retroperitoneal radiotherapy), age at primary diagnosis, period (before and after 1997 when immunohistochemistry was introduced at the Copenhagen University Hospital), and histological type of the primary tumour. Patients with relapsed stage I tumours were grouped according to relapse treatment. BEP-treated patients who also received retroperitoneal radiotherapy (n = 71) were included in the BEP-treated group. Proportional hazards tests and diagnostics were based on weighted residuals [12] . The statistical analysis was carried out with R version 3.0.2 [13] .
results
Demographic data on the screened and unscreened cohorts are shown in Table 1 . The screened cohort consisted of 4130 patients. Metachronous cancers were found in 58 patients ( Figure 1 Metachronous GCC developed in 53 of 3949 (1.3%) patients without CIS in the screened cohort ( Figure 1 , Table 2 ). Initial biopsies were collected from 45 of the 53 patients, and, after revision, CIS was detected in the samples from 17 out of 45 (38%) patients. Revision was not possible for eight patients, as the samples were lost or not representative.
The unscreened cohort comprised 462 patients, with 15 (3.2%) cases of metachronous GCC (Figure 1 , Tables 1 and 2 ).
The 20-year cumulative incidence of metachronous GCC was 1.9% (95% CI 1.4-2.5) in the screened population and 3.1% (95% CI 1.5-4.6) in the unscreened cohort (P = 0.097) (Figure 2 ). In the multivariate model, HR was 1.59 (95% CI 0.85-2.95) for the unscreened cohort in comparison with the screened cohort (P = 0.144). To prevent one case of metachronous GCC, the number of patients needed to screen measured at 20 years was 83 (although insignificant). Treatment with BEP (HR, 0.35; P = 0.002) and older age (HR, 0.52 per 10 years; P < 0.001) were significantly correlated with a decreased risk for metachronous GCC. No correlation was found between time of diagnosis of the primary GCC before 1997 and risk for metachronous GCC (HR, 1.00, P = 0.999) ( Table 3) .
The second tumour was stage I for 85% of all patients with metachronous GCC (62/73). Five patients with metachronous GCC died: one from progressive GCC, two from cardiovascular disease, one from surgical complications, and one from sarcoma.
discussion
We have reported the incidence of metachronous GCC in a nation-wide, population-based, screened cohort, with very long follow-up time. Our study is novel and unique in this aspect, and our evaluation revealed important findings. First, the number of metachronous GCC cases in the screened cohort was high. This may be due to the fact that CIS is not scattered all over the testicle as previously assumed and therefore not diagnosed by one or two biopsies [14] [15] [16] . We found no significant difference between the risk of metachronous GCC in the two cohorts. CIS in our patient cohort was diagnosed over a period of 24 years, during which time immunohistochemical staining for CIS markers was introduced, and the methods (including However, we found no difference in risk for metachronous GCC between patients in whom primary GCC was diagnosed before and after 1997. Secondly, the risk of the unscreened cohort for metachronous GCC at 20 years was <5%. A proportion of the patients received BEP, which may explain the smaller number of metachronous GCC cases than the known prevalence of CIS. Furthermore, in theory, CIS might regress spontaneously. Due to the scarcity of the unscreend cohort, the range of the confidence interval around the estimated risk was wide.
Other studies have shown cumulative incidences of metachronous GCC of 1.9%-5.2% at 15-20 years in unscreened populations [17] [18] [19] . Fosså et al. [17] reported the results of a large (15) 4 (12) 7 (13) 3 (43) 0 (0) 3 (20) GCC, germ-cell cancer; CIS, carcinoma in situ; IQR, inter-quartile range. As shown in the present study, systemic treatment reduces or delays the number of metachronous cancers and details of treatment-adjuvant or for metastatic disease-were not reported in the US study. Besides, metachronous GCC rates might differ between countries. In another cohort of 2850 Danish men, diagnosed 1960-1979, the cumulative incidence of metachronous GCC at 20 years was 5.2% (95% CI 3.7-6.7) [18] . The majority of these patients were treated in the pre-cisplatin era, and the study results may reflect less impact from previous treatment modalities on development of metachronous GCC. Routine screening for CIS in the contralateral testicle in GCC patients has not been adopted worldwide but is practised in Denmark and most centres in Austria and Germany. The controversy is due to opposing views on what serves the patient best in terms of morbidity. Early detection and treatment of CIS can obviate potential later bilateral orchiectomy and, in some cases, systemic treatment. Bilateral orchiectomy requires lifelong hormone replacement therapy. Furthermore, a testicular biopsy provides an opportunity to advise patients about their future fertility, which is often a major issue in these young patients.
Disadvantages include post-biopsy complications, i.e. haematoma and infection, with a prevalence of <3% reported in a study of two-site biopsy [20] . The suppressive effect of BEP on CIS means that not all CIS cells will progress to invasive GCC, and some patients will receive unnecessary radiotherapy. In our study, treatment with BEP decreased the risk for metachronous GCC from that with surveillance alone to one-third. Radiotherapy can effectively eradicate CIS, but results in a 'sertoli-cell-only' syndrome, leaving the patients sterile. Most of the patients with CIS in our cohort had received radiotherapy at doses of 14-20 Gy. Invasive tumours developed in 3 of 38 (8%) patients treated with 14 Gy, entailing this an insufficient dose. So far, we have observed no relapses in our cohort with higher radiotherapy doses, but failures have been reported in the literature after treatment with 16, 18, or 20 Gy [21, 22] .
The largest study on metachronous GCC showed no increased mortality of patients with metachronous GCC compared with patients with unilateral GCC [17] . In a Dutch study, patients with metachronous GCC had a twofold higher risk for a non-testis second cancer than those with unilateral GCC after adjustment for age and treatment for the primary GCC [19] . A proportion of the patients were treated before 1985, when radiation fields were more extensive. In the present study, only one patient with metachronous GCC died due to a second cancer (sarcoma), so far.
After revising primary CIS-negative biopsies in our study, we re-classified CIS in 17 out of 45 (38%) cases, when using up-todate methodology. We found that common reasons for diagnostic failure were the quality of the specimen (i.e. technical preparation and/or size), inappropriate over-fixation with formalin, and lack of recognition of CIS in the absence of immunostaining for a marker. For comparison, in a study by Dieckmann et al., 21 patients with GCC had the primary CIS-negative biopsy revised with thoroughly step-sectioning of the specimen and immunohistochemistry. The authors found CIS in 5 out of 21 cases (24%), corresponding well to our results [23] . It has been suggested that two biopsies of the contralateral testis may be more appropriate. A prospective study of 2318 patients who underwent two-site biopsy showed a discordance in 31.1% of the biopsy pairs [24] , predominantly comprising samples from normal-sized testicles. The incidence of CIS in that study was 5.1%, whereas it was 4.4% in our cohort. Double biopsy increases sensitivity, but randomized studies are required to ascertain the gain in relation to later development of metachronous GCC. In view of the low incidence of contralateral CIS, it could be preferable to offer contralateral biopsy exclusively to high-risk patients. A history of cryptorchidism or young age combined with low sperm concentration or small testis volume increases the risk for contralateral CIS [3] ; however, a proportion of CIS cases are found in patients with normal spermatogenesis and normal testicular size [24] and will be missed in a selected programme.
The present data show that an un-selected screening programme is not optimal. Re-examination found CIS in 38% of primary CIS-negative samples from metachronous cases. Highquality surgery and optimal preparation of specimens may reduce the number of false-negative biopsies but due to the focal nature of CIS in the testicle, CIS-positive cases will continue to be overlooked. Some cases of CIS will not progress to cancer, or the progression will be delayed due to chemotherapy.
Our comprehensive national coverage and extensive clinical information obtained from medical files ensure a high level of data validity. Linkage to national registries provided us with information on bilateral cancers that developed after the end of clinical follow-up. Limitations are the retrospective nature, the small number of patients in the unscreened cohort, and the non-randomized study design. However, the present dataset is unique in many ways and no one else has data which may further clarify the effect of screening for CIS.
In the present study, we found no significant difference in the risk of metachronous GCC between a screened and an unscreened cohort. Based on our results, single-site biopsy screening and treatment for CIS does not reduce the risk for metachronous GCC, and there is no evidence to support screening in its present form in unselected patients.
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